abstract |
A pharmaceutical combination, includes an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. One combination includes an inhibitor of S100A4 as a Wnt-signaling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. A pharmaceutical composition can include the combination. The combination or composition can be used in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis. |